PATENT CLAIM ANALYSIS

Application Number: 15993287
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-12
Patent Classification: ["514", "04400A"]

Abstract:
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.

Claim (Index 12):
A pharmaceutical composition, comprising an antisense oligomer conjugate of  claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 93.0
- Lexical Diversity: 1.04762
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13219401', '14240832', '14368307', '15339069', '13307926']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7954447898794378
- 35 USC 102 Novelty (BERT): 0.5433949731444864
- Combined Prediction Score: 0.7702398082059426
- Mean Citation Score: 388.39622
- Max Citation Score: 426.69928
- Similarity Product: 292.4738313105583

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test